PAVBLU (aflibercept-ayyh) · Amgen
PAVBLU (aflibercept-ayyh) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of several serious retinal conditions. It is used to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema. The drug is also approved for the treatment of patients with diabetic retinopathy. As a therapeutic agent, it addresses pathologies characterized by abnormal blood vessel growth and vascular permeability in the eye.
How PAVBLU Works
PAVBLU functions as a soluble decoy receptor that binds to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF). By capturing these growth factors, the drug prevents them from binding to and activating their cognate receptors, VEGFR-1 and VEGFR-2, on the surface of endothelial cells. This inhibition interrupts the signaling pathways that lead to neovascularization and increased vascular permeability. Consequently, the drug helps manage the biological processes that drive the progression of various retinal vascular diseases.
Details
- Status
- Prescription
- First Approved
- 2024-08-23
- Revenue
- $287M (Q2-2026)
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
Latest PAVBLU News
All PAVBLU news →PAVBLU Approval History
What PAVBLU Treats
5 indicationsPAVBLU is approved for 5 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
PAVBLU is a lower-cost alternative to Eylea with no clinically meaningful differences. Requires prescriber approval to substitute.
PAVBLU Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to PAVBLU
3 of 11FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Amgen's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PAVBLU FDA Label Details
Indications & Usage
FDA Label (PDF)PAVBLU is indicated for the treatment of: PAVBLU is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)
Pro Intelligence Preview
Deep insights for PAVBLU
Revenue Insights
- • Q2-2026: $287M
- • Historical trend analysis
Patent Timeline
- • Patent expiration dates
- • Generic/biosimilar risk
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 11 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.